Hepatocellular Carcinoma Clinical Trials 2024

What are the top hospitals conducting hepatocellular carcinoma research?

When it comes to the battle against hepatocellular carcinoma, or liver cancer, several top hospitals are leading the way in clinical trials. In New york City, Memorial Sloan Kettering Cancer Center is at the forefront with five active trials dedicated to hepatocellular carcinoma and a notable history of 20 completed trials since their first recorded study in 2007. Meanwhile, M D Anderson Cancer Center in Houston has also emerged as a key player with five ongoing clinical trials and an impressive record of 27 previous studies focused on this type of liver cancer. Interestingly, MD Anderson Cancer Center appears on this list twice, highlighting its significant contribution to hepatocellular carcinoma research. With four active trials and 13 all-time conducted studies since its inaugural trial in 2007, they are clearly making strides towards improved treatment options for patients.

In addition to these renowned institutions, City of Hope located in Duarte is making noteworthy progress with four active hepatocellular carcinoma trials and a total of 13 completed studies dating back to their first recorded trial in 2002. Lastly but certainly not least,Dana Farber Cancer Institute situated in Boston joins the ranks with four ongoing clinical trials aimed at tackling hepatocellular carcinoma while having made significant contributions through nine previously conducted investigations; their pioneering trial was initiated only seven years ago,in2014.

These top hospitals represent beacons of hope for individuals battling hepatocellular carcinoma by spearheading innovative research efforts that may lead to groundbreaking treatments or even potential cures. Through collaboration between medical professionals and relentless dedication fueled by compassion for patients affected by this aggressive form of cancer these facilities bring us closer toward finding effective solutions that can improve outcomes for those impacted worldwide.

Which are the best cities for hepatocellular carcinoma clinical trials?

When it comes to hepatocellular carcinoma clinical trials, several cities have emerged as top contenders for research and advancements in treatment. Leading the way is New york, New York, with 35 active trials focusing on promising treatments like Nivolumab, SRF388, and Pembrolizumab. Following closely behind is Houston, Texas, with 31 ongoing studies exploring Meclizine Oral Tablet, cabozantinib, and Resin microspheres containing yttrium-90 (Y-90). Los Angeles, California also joins the list with 25 active trials investigating treatments such as Nivolumab and Telatinib. These cities offer individuals battling hepatocellular carcinoma access to cutting-edge clinical trials that hold promise for improved outcomes and future breakthroughs in care.

Which are the top treatments for hepatocellular carcinoma being explored in clinical trials?

Hepatocellular carcinoma, a formidable foe, is currently under scrutiny as clinical trials explore potential treatments. Leading the charge is nivolumab, with six active and 49 all-time hepatocellular carcinoma trials since its introduction in 2012. Not far behind is pembrolizumab, making waves with five ongoing trials and an impressive track record of 38 all-time studies since 2016. Atezolizumab follows suit closely with four active trials and 34 all-time hepatocellular carcinoma investigations initiated in 2018. Durvalumab also shows promise, participating in three current trials while accumulating a respectable repertoire of 30 previous studies since its listing in 2015. Lastly, SRF388 may be relatively new to the scene but has already gained traction through two ongoing hepatocellular carcinoma trials following its debut just last year (2020). As researchers delve deeper into these innovative therapies, hope shines brighter for those affected by this challenging cancer.

What are the most recent clinical trials for hepatocellular carcinoma?

Recent clinical trials for hepatocellular carcinoma offer promising approaches in the fight against this challenging form of liver cancer. One notable study explores the combination of Livmoniplimab and Budigalimab in Arm 3, presenting a potential breakthrough in treatment during Phase 2 trials. Tegavivint's single-agent dosing regimen also shows promise as it progresses through both Phase 1 and Phase 2 studies. Additionally, Transarterial Embolization with Hydroxychloroquine demonstrates potential benefits for patients participating in combined Phase 1 and Phase 2 trials. These recent advancements bring hope to individuals affected by hepatocellular carcinoma, while further understanding its complexities paves the way for improved treatments in the future.

What hepatocellular carcinoma clinical trials were recently completed?

Several recent clinical trials have reached completion, offering valuable insights into the treatment of hepatocellular carcinoma. The investigational therapy RO7119929, sponsored by Hoffmann-La Roche, concluded in July 2020. In June 2019, two trials wrapped up: one involving the use of 68Ga-PSMA-11 PET/MRI and another investigating nivolumab under the sponsorship of Ajit H. Goenka, MD and National Cancer Institute (NCI), respectively. These studies were followed by various other completed trials between 2016 and 2018 that explored therapies such as Pembrolizumab, Cabozantinib, Atezolizumab, derazantinib, Ipilimumab, lenvatinib, H3B-6527,and Tremelimumab from multiple institutions and companies including Bayer and M.D Anderson Cancer Center among others – signifying a dedicated effort to advance treatments for hepatocellular carcinoma patients.